pubmed-article:20629023 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C0033325 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C1512162 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C0023467 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C0004927 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C0677874 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C1578536 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C1511572 | lld:lifeskim |
pubmed-article:20629023 | lifeskim:mentions | umls-concept:C2348205 | lld:lifeskim |
pubmed-article:20629023 | pubmed:issue | 21 | lld:pubmed |
pubmed-article:20629023 | pubmed:dateCreated | 2010-10-25 | lld:pubmed |
pubmed-article:20629023 | pubmed:abstractText | Patients with newly diagnosed acute myeloid leukemia (AML) often have residual leukemia in the bone marrow 10 to 14 days after the start of induction therapy. Some cooperative groups administer a second cycle of similar induction therapy on Day 14 if there is residual leukemia. It is a common perception that the presence of residual leukemia at that point predicts a worse prognosis irrespective of the therapy received. The objective of this study was to determine whether patients who required a second cycle of induction (given on or about Day 14) to achieve complete remission (CR) had a worse prognosis than patients who achieved CR after only 1 cycle, because a worse prognosis may alter postremission therapy. | lld:pubmed |
pubmed-article:20629023 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20629023 | pubmed:language | eng | lld:pubmed |
pubmed-article:20629023 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20629023 | pubmed:citationSubset | AIM | lld:pubmed |
pubmed-article:20629023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:20629023 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:20629023 | pubmed:month | Nov | lld:pubmed |
pubmed-article:20629023 | pubmed:issn | 0008-543X | lld:pubmed |
pubmed-article:20629023 | pubmed:author | pubmed-author:RoweJacob MJM | lld:pubmed |
pubmed-article:20629023 | pubmed:author | pubmed-author:LitzowMark... | lld:pubmed |
pubmed-article:20629023 | pubmed:author | pubmed-author:WiernikPeter... | lld:pubmed |
pubmed-article:20629023 | pubmed:author | pubmed-author:TallmanMartin... | lld:pubmed |
pubmed-article:20629023 | pubmed:author | pubmed-author:LazarusHillar... | lld:pubmed |
pubmed-article:20629023 | pubmed:author | pubmed-author:KimHaesook... | lld:pubmed |
pubmed-article:20629023 | pubmed:author | pubmed-author:CassilethPete... | lld:pubmed |
pubmed-article:20629023 | pubmed:copyrightInfo | Copyright © 2010 American Cancer Society. | lld:pubmed |
pubmed-article:20629023 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:20629023 | pubmed:day | 1 | lld:pubmed |
pubmed-article:20629023 | pubmed:volume | 116 | lld:pubmed |
pubmed-article:20629023 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:20629023 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:20629023 | pubmed:pagination | 5012-21 | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:meshHeading | pubmed-meshheading:20629023... | lld:pubmed |
pubmed-article:20629023 | pubmed:year | 2010 | lld:pubmed |
pubmed-article:20629023 | pubmed:articleTitle | Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group. | lld:pubmed |
pubmed-article:20629023 | pubmed:affiliation | Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa, Israel. rowe@jimmy.harvard.edu | lld:pubmed |
pubmed-article:20629023 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:20629023 | lld:pubmed |